Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma
Clinical trial NCT04351308 · UNKNOWN
Trial details
- NCT number
- NCT04351308
- Sponsor
- Peking University People's Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-05-01
- Primary completion
- 2022-09-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.